Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in
individuals with new onset T1DM will improve insulin secretion (C-peptide production)
compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators:
American Diabetes Association Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Juvenile Diabetes Research Foundation National Institute of Allergy and Infectious Diseases (NIAID)